1. PB1837: ADDITION OF A THIRD, NON-TARGETED, AGENT TO CYTARABINE- AND ANTHRACYCLINE-BASED INDUCTION CHEMOTHERAPY FOR ACUTE MYELOBLASTIC LEUKEMIA INCREASES COMPLETE REMISSIONS AND TREATMENT-RELATED MORTALITY. (23rd June 2022) Authors: Pereira, M.; Marques, G.; Sarmento-Ribeiro, A.-B. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1717 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗